David Gailani

Title: David Gailani: Innovator in Monoclonal Antibody Research

Introduction

David Gailani is a prominent inventor based in Franklin, TN (US), known for his significant contributions to the field of monoclonal antibodies. With a total of 9 patents to his name, he has made remarkable strides in developing innovative solutions for medical challenges, particularly in the area of thrombosis.

Latest Patents

One of Gailani's latest patents focuses on anti-factor XI monoclonal antibodies and methods of use thereof. This patent describes compositions and methods for inhibiting thrombosis without compromising hemostasis. The compositions include anti-factor XI monoclonal antibodies (aXIMabs) that can bind to an epitope on the heavy chain of human FXI, specifically the A3 domain. Additionally, the patent covers epitope-binding fragments, variants, and derivatives of these monoclonal antibodies, as well as cell lines that produce these antibody compositions and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure also includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies or their derivatives in a pharmaceutically acceptable carrier. The methods outlined in the patent involve administering these compositions to subjects in need for various purposes, including inhibiting thrombosis, reducing the required dose of antithrombotic agents, treating metastatic cancer, or addressing acute inflammatory reactions.

Career Highlights

Throughout his career, David Gailani has worked with esteemed institutions such as Oregon Health & Science University and Vanderbilt University. His work has significantly impacted the field of biomedical research, particularly in the development of therapeutic agents that target specific pathways in disease processes.

Collaborations

Gailani has collaborated with notable colleagues, including Andras Gruber and Erik Tucker, contributing to a rich exchange of ideas and advancements in their shared field of research.

Conclusion

David Gailani's innovative work in monoclonal antibody research exemplifies the potential of scientific inquiry to address critical health issues. His contributions continue to pave the way for advancements in medical treatments and therapies.